Explore Immune Cell Killing Assays for Immunotherapy Research
By harnessing and enhancing the innate powers of the immune system to fight cancer, immunotherapy has transformed the research landscape for the better. Significant challenges remain, however, such as an inability to reliably predict immune cell-based therapeutic efficacy and response. While methods have been developed to screen and evaluate immune cell killing efficacy, there still exists a need for robust in vitro assays to accurately predict therapeutic behavior in vivo.
Measure immune cell killing directly, at low, physiologically relevant effector to target (E:T) ratios and generate quantitative cytolytic data to accurately evaluate potency with Agilent xCELLigence Real Time Cell Analysis (RTCA) instruments. Spend less time in lab with a simple, sensitive, and reproducible immune cell killing assay.
Cancer immunotherapy is constantly evolving, and it is hard to keep up with the latest advancements in assay technology. Catch up on the latest selected publications featuring xCELLigence and key supporting information.
Download the updated xCELLigence RTCA Cancer Immunotherapy Handbook to learn about a simple and high throughput workflow to easily evaluate:
- Antibody-dependent cell-mediated cytolysis (ADCC)
- Bispecific T cell engagers (BiTEs) and bispecific antibodies
- Checkpoint inhibitors
- Combination therapies
- Genetically engineered T cell-mediated cell killing
- Oncolytic viruses
- Liquid tumor killing